AMD Gene Therapy Prospects Swept Downhill With Avalanche
This article was originally published in Scrip
Avalanche Biotechnologies was true to its name on Aug. 14, opening down 16% on the previous day's close at $11.64 and continuing to slide to as low as $9.36 by mid-afternoon trading. As the company revealed that it would not be progressing into Phase IIb with its lead candidate, any lingering hopes of a gene therapy for wet age-related macular degeneration reaching the market any time soon were soundly dashed.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.